RelieVRx RVX-2052

GUDID 00850038247072

RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive treatment for chronic lower back pain (CLBP).

Appliedvr, Inc.

Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system Pain relief virtual reality system
Primary Device ID00850038247072
NIH Device Record Key563dd570-a3da-4572-81f6-cdbf8399fa9e
Commercial Distribution StatusIn Commercial Distribution
Brand NameRelieVRx
Version Model NumberRVX-2052
Catalog NumberRVX-2052
Company DUNS080429668
Company NameAppliedvr, Inc.
Device Count1
DM Exemptfalse
Pre-market Exemptfalse
MRI Safety StatusLabeling does not contain MRI Safety Information
Human Cell/Tissue Productfalse
Device Kitfalse
Device Combination Productfalse
Single Usefalse
Lot Batchfalse
Serial Numberfalse
Manufacturing Datefalse
Expiration Datefalse
Donation Id Numberfalse
Contains Natural Rubber Latexfalse
Labeled No Natural Rubber Latexfalse
RX Perscriptiontrue
OTC Over-The-Counterfalse

Customer Support Contacts

Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com
Phone844-728-4487
Emailsupport@avrpathway.com

Device Identifiers

Device Issuing AgencyDevice ID
GS100850038247072 [Primary]

FDA Pre-market Approvals/Notifications & deNovo

FDA Product Code

QRAVirtual Reality Behavioral Therapy Device For Pain Relief

Sterilization

Steralize Prior To Usefalse
Device Is Sterilefalse

Device Entry Metadata

Public Version StatusNew
Device Record StatusPublished
Public Version Number1
Public Version Date2024-02-15
Device Publish Date2024-02-07

On-Brand Devices [RelieVRx]

00850038247010RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247027RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247041RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247034RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247058RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247065RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247096RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247089RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre
00850038247072RelieVRx is an at-home immersive virtual reality (VR) pain treatment indicated as adjunctive tre

Trademark Results [RelieVRx]

Mark Image

Registration | Serial
Company
Trademark
Application Date
RELIEVRX
RELIEVRX
97381930 not registered Live/Pending
AppliedVR, Inc.
2022-04-26
RELIEVRX
RELIEVRX
88281369 not registered Live/Pending
AppliedVR, Inc.
2019-01-29

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.